Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2022

View Archived Issues

New murine model of AIH developed using a human liver protein

Science & Technology Development Fund Authority presents new antiviral nucleosides

New DDR1 and/or DDR2 inhibitors identified at Galapagos

PI3K-delta inhibitors patented by Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical

Sichuan Haisco Pharmaceutical discovers polymerase basic protein 2 inhibitors

Beijing Findcure Biosciences divulges new tyrosine-protein kinase receptor UFO inhibitors

SLAMF3 and SLAMF4 targeting for treating hematopoietic cancers

HMGB1 restricts EPO signaling, contributing to anemia of inflammation

CCR4 mediates postoperative pain through skin dendritic cells

Sarepta and GenEdit report progress under collaboration for neuromuscular diseases

Catalog of protein isoforms in blood cells can predict organ rejection

Skye reports data on SBI-100 ophthalmic nanoemulsion in preclinical glaucoma model

Neuronal PFKFB3 upregulation involved in ceroid lipofuscinosis

Discovery of novel ATX inhibitor with promising antifibrosis efficacy in rodents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...